EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effect of Tocilizumab on the outcome of patients with severe COVID-19 with cytokine storm syndrome in a sample of Iraqi patients

Abdul Hameed Alqaseer, Alaa Kareem Dhayef, Ammar Waham Ashor

Journal of the Pakistan Medical Association · 2024

DOI: 10.47391/jpma-bagh-16-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Pakistan Medical Association, 2024. Verfasst von Abdul Hameed Alqaseer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mustansiriyah University, Baghdad, Iraq. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cytokine Release Syndrome, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine whether tocilizumab improved outcomes of patients hospitalised with severe coronavirusdisease-2019 cytokine storm syndrome.

Method

The case-control study was conducted at Al-Yarmouk Teaching Hospital, Baghdad, and Al Shatra GeneralHospital, Thi Qar, Iraq, from September 2020 to March 2021, and comprised patients with severe acquiredrespiratory syndrome-corona virus-2 pneumonia who were not candidates for mechanical ventilation and receiveda single-dose intravenous infusion of tocilizumab 8mg/kg in group A. The outcomes were compared with patientsin group B who received only standard care. Data was analysed using SPSS 26.

Results

Of the 60 patients, 30(50%) were in group A; 22(73.3%) males and 8(26.7%) females with mean age56.63±10.92 years. There were 30(50%) patients in control group B; 24(80%) males and 6(20%) females with meanage 54.8±6.18 (p>0.05). Group A showed significant changes compared to group B in the levels of interleukin-6,serum ferritin, D-dimer, procalcitonin, lymphocytes count and oxygen saturation (p0.05).

Conclusions

Majority of the acute phase inflammatory markers were reduced significantly by treatment withtocilizumab.Key Words: Tocilizumab, fibrin, Interleukin, Procalcitonin, Cytokine, Infusions, Intravenous, Oxygen Saturation,Respiration, Artificial, Coronavirus, Lymphocytes, Ferritins

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCytokine Release SyndromeCOVID-19COVID-19 Drug TreatmentSARS-CoV-2HumansFemaleMaleMiddle AgedIraqCase-Control StudiesProcalcitoninTreatment OutcomeInterleukin-6AdultFibrin Fibrinogen Degradation ProductsAgedFerritins

Stichwörter der Autor:innen

Tocilizumab, fibrin, Interleukin, Procalcitonin, Cytokine, Infusions, Intraveno…

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedProcalcitoninInterleukin-6Fibrin Fibrinogen Degradation Productsfibrin fragment DFerritins

Autor:innen und Institutionen

  • Department of Internal Medicine, Mustansiriyah University, Baghdad, Iraq.
  • Department of Internal Medicine, Al-Yarmook Teaching Hospital, Baghdad, Iraq.

Zitieren

APA

Alqaseer, A. H., Dhayef, A. K., & Ashor, A. W. (2024). The Effect of Tocilizumab on the outcome of patients with severe COVID-19 with cytokine storm syndrome in a sample of Iraqi patients. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma-bagh-16-25

Vancouver

Alqaseer AH, Dhayef AK, Ashor AW. The Effect of Tocilizumab on the outcome of patients with severe COVID-19 with cytokine storm syndrome in a sample of Iraqi patients. Journal of the Pakistan Medical Association. 2024. doi:10.47391/jpma-bagh-16-25

BibTeX
@article{Alqaseer2024,
  author = {Alqaseer, Abdul Hameed and Dhayef, Alaa Kareem and Ashor, Ammar Waham},
  title = {The Effect of Tocilizumab on the outcome of patients with severe COVID-19 with cytokine storm syndrome in a sample of Iraqi patients},
  journal = {Journal of the Pakistan Medical Association},
  year = {2024},
  doi = {10.47391/jpma-bagh-16-25}
}
Kostenlos starten →